The global PD-L1 and PIK3CA Testing market size is predicted to grow from US$ 878 million in 2025 to US$ 2805 million in 2031; it is expected to grow at a CAGR of 21.4% from 2025 to 2031.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti鈥揚D-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.
PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.
North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.
Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.
The 鈥淧D-L1 and PIK3CA Testing Industry Forecast鈥� looks at past sales and reviews total world PD-L1 and PIK3CA Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-L1 and PIK3CA Testing sales for 2025 through 2031. With PD-L1 and PIK3CA Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-L1 and PIK3CA Testing industry.
This Insight Report provides a comprehensive analysis of the global PD-L1 and PIK3CA Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-L1 and PIK3CA Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global PD-L1 and PIK3CA Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-L1 and PIK3CA Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-L1 and PIK3CA Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-L1 and PIK3CA Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
PD-L1 Testing
PIK3CA Testing
Segmentation by Application:
Hospital
Diagnostic Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PD-L1 and PIK3CA Testing Market Size (2020-2031)
2.1.2 PD-L1 and PIK3CA Testing Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for PD-L1 and PIK3CA Testing by Country/Region (2020, 2024 & 2031)
2.2 PD-L1 and PIK3CA Testing Segment by Type
2.2.1 PD-L1 Testing
2.2.2 PIK3CA Testing
2.3 PD-L1 and PIK3CA Testing Market Size by Type
2.3.1 PD-L1 and PIK3CA Testing Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global PD-L1 and PIK3CA Testing Market Size Market Share by Type (2020-2025)
2.4 PD-L1 and PIK3CA Testing Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Others
2.5 PD-L1 and PIK3CA Testing Market Size by Application
2.5.1 PD-L1 and PIK3CA Testing Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global PD-L1 and PIK3CA Testing Market Size Market Share by Application (2020-2025)
3 PD-L1 and PIK3CA Testing Market Size by Player
3.1 PD-L1 and PIK3CA Testing Market Size Market Share by Player
3.1.1 Global PD-L1 and PIK3CA Testing Revenue by Player (2020-2025)
3.1.2 Global PD-L1 and PIK3CA Testing Revenue Market Share by Player (2020-2025)
3.2 Global PD-L1 and PIK3CA Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PD-L1 and PIK3CA Testing by Region
4.1 PD-L1 and PIK3CA Testing Market Size by Region (2020-2025)
4.2 Global PD-L1 and PIK3CA Testing Annual Revenue by Country/Region (2020-2025)
4.3 Americas PD-L1 and PIK3CA Testing Market Size Growth (2020-2025)
4.4 APAC PD-L1 and PIK3CA Testing Market Size Growth (2020-2025)
4.5 Europe PD-L1 and PIK3CA Testing Market Size Growth (2020-2025)
4.6 Middle East & Africa PD-L1 and PIK3CA Testing Market Size Growth (2020-2025)
5 Americas
5.1 Americas PD-L1 and PIK3CA Testing Market Size by Country (2020-2025)
5.2 Americas PD-L1 and PIK3CA Testing Market Size by Type (2020-2025)
5.3 Americas PD-L1 and PIK3CA Testing Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-L1 and PIK3CA Testing Market Size by Region (2020-2025)
6.2 APAC PD-L1 and PIK3CA Testing Market Size by Type (2020-2025)
6.3 APAC PD-L1 and PIK3CA Testing Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe PD-L1 and PIK3CA Testing Market Size by Country (2020-2025)
7.2 Europe PD-L1 and PIK3CA Testing Market Size by Type (2020-2025)
7.3 Europe PD-L1 and PIK3CA Testing Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-L1 and PIK3CA Testing by Region (2020-2025)
8.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type (2020-2025)
8.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global PD-L1 and PIK3CA Testing Market Forecast
10.1 Global PD-L1 and PIK3CA Testing Forecast by Region (2026-2031)
10.1.1 Global PD-L1 and PIK3CA Testing Forecast by Region (2026-2031)
10.1.2 Americas PD-L1 and PIK3CA Testing Forecast
10.1.3 APAC PD-L1 and PIK3CA Testing Forecast
10.1.4 Europe PD-L1 and PIK3CA Testing Forecast
10.1.5 Middle East & Africa PD-L1 and PIK3CA Testing Forecast
10.2 Americas PD-L1 and PIK3CA Testing Forecast by Country (2026-2031)
10.2.1 United States Market PD-L1 and PIK3CA Testing Forecast
10.2.2 Canada Market PD-L1 and PIK3CA Testing Forecast
10.2.3 Mexico Market PD-L1 and PIK3CA Testing Forecast
10.2.4 Brazil Market PD-L1 and PIK3CA Testing Forecast
10.3 APAC PD-L1 and PIK3CA Testing Forecast by Region (2026-2031)
10.3.1 China PD-L1 and PIK3CA Testing Market Forecast
10.3.2 Japan Market PD-L1 and PIK3CA Testing Forecast
10.3.3 Korea Market PD-L1 and PIK3CA Testing Forecast
10.3.4 Southeast Asia Market PD-L1 and PIK3CA Testing Forecast
10.3.5 India Market PD-L1 and PIK3CA Testing Forecast
10.3.6 Australia Market PD-L1 and PIK3CA Testing Forecast
10.4 Europe PD-L1 and PIK3CA Testing Forecast by Country (2026-2031)
10.4.1 Germany Market PD-L1 and PIK3CA Testing Forecast
10.4.2 France Market PD-L1 and PIK3CA Testing Forecast
10.4.3 UK Market PD-L1 and PIK3CA Testing Forecast
10.4.4 Italy Market PD-L1 and PIK3CA Testing Forecast
10.4.5 Russia Market PD-L1 and PIK3CA Testing Forecast
10.5 Middle East & Africa PD-L1 and PIK3CA Testing Forecast by Region (2026-2031)
10.5.1 Egypt Market PD-L1 and PIK3CA Testing Forecast
10.5.2 South Africa Market PD-L1 and PIK3CA Testing Forecast
10.5.3 Israel Market PD-L1 and PIK3CA Testing Forecast
10.5.4 Turkey Market PD-L1 and PIK3CA Testing Forecast
10.6 Global PD-L1 and PIK3CA Testing Forecast by Type (2026-2031)
10.7 Global PD-L1 and PIK3CA Testing Forecast by Application (2026-2031)
10.7.1 GCC Countries Market PD-L1 and PIK3CA Testing Forecast
11 Key Players Analysis
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Information
11.1.2 Agilent Technologies PD-L1 and PIK3CA Testing Product Offered
11.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Agilent Technologies Main Business Overview
11.1.5 Agilent Technologies Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche PD-L1 and PIK3CA Testing Product Offered
11.2.3 Roche PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 QIAGEN
11.3.1 QIAGEN Company Information
11.3.2 QIAGEN PD-L1 and PIK3CA Testing Product Offered
11.3.3 QIAGEN PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 QIAGEN Main Business Overview
11.3.5 QIAGEN Latest Developments
11.4 EntroGen
11.4.1 EntroGen Company Information
11.4.2 EntroGen PD-L1 and PIK3CA Testing Product Offered
11.4.3 EntroGen PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 EntroGen Main Business Overview
11.4.5 EntroGen Latest Developments
11.5 Amoy Diagnostics
11.5.1 Amoy Diagnostics Company Information
11.5.2 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Offered
11.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Amoy Diagnostics Main Business Overview
11.5.5 Amoy Diagnostics Latest Developments
11.6 ACCB Biotech
11.6.1 ACCB Biotech Company Information
11.6.2 ACCB Biotech PD-L1 and PIK3CA Testing Product Offered
11.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 ACCB Biotech Main Business Overview
11.6.5 ACCB Biotech Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
